Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Canada Graduate Scholarships-Master's Program

FY 2014-15

Summary
Given their effectiveness as preventative measures, many vaccines are publicly funded by the government to facilitate their uptake and ensure equitable access for all residents. As with any intervention, a critical factor in deciding whether or not to fund a vaccine is understanding its cost-effectiveness. The focus of the proposed study is Streptococcus pneumoniae, a bacterium that causes invasive (e.g. bacteremia, meningitis) and non-invasive pneumococcal disease (e.g. otitis media, pneumonia). In the recent "Ontario Burden of Infectious Disease Study", S. pneumoniae was ranked the second most burdensome pathogen in the province, above HIV, C.difficile and E.coli. Given its significant morbidity and mortality, two vaccines targeting S.pneumoniae have been funded in Canada: the pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal conjugate vaccine (PCV13). Although the original 7-valent PCV was funded for infants in 2002, until recently no quantitative evidence existed on its efficacy in older adults. However, based on recent clinical trial data, Health Canada approved an expansion of PCV13's indication to include older adults (50+) in 2012. However, at present, PCV13 is not publicly funded for older adults in any province across Canada and its cost-effectiveness remains unknown. As a result, the objective of the present study is to evaluate the cost-effectiveness of replacing the PPV23 with PCV13 in older adults from the perspective of the provincial healthcare system. Using a health economic model to simulate the effectiveness of each vaccine for the Ontario population, the proposed study will determine the costs and health benefits associated with each strategy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331313
Name
O'Reilly Ryan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canada Graduate Scholarships-Master's Program
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cost-Effectiveness; Economic Evaluation; Health Economics; Health Technology Assessment; Infectious Diseases; Pneumococcal Vaccination; Public Funding; Seniors; Streptococcus Pneumoniae; Vaccine
Abstract
Given their effectiveness as preventative measures, many vaccines are publicly funded by the government to facilitate their uptake and ensure equitable access for all residents. As with any intervention, a critical factor in deciding whether or not to fund a vaccine is understanding its cost-effectiveness. The focus of the proposed study is Streptococcus pneumoniae, a bacterium that causes invasive (e.g. bacteremia, meningitis) and non-invasive pneumococcal disease (e.g. otitis media, pneumonia). In the recent "Ontario Burden of Infectious Disease Study", S. pneumoniae was ranked the second most burdensome pathogen in the province, above HIV, C.difficile and E.coli. Given its significant morbidity and mortality, two vaccines targeting S.pneumoniae have been funded in Canada: the pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal conjugate vaccine (PCV13). Although the original 7-valent PCV was funded for infants in 2002, until recently no quantitative evidence existed on its efficacy in older adults. However, based on recent clinical trial data, Health Canada approved an expansion of PCV13's indication to include older adults (50+) in 2012. However, at present, PCV13 is not publicly funded for older adults in any province across Canada and its cost-effectiveness remains unknown. As a result, the objective of the present study is to evaluate the cost-effectiveness of replacing the PPV23 with PCV13 in older adults from the perspective of the provincial healthcare system. Using a health economic model to simulate the effectiveness of each vaccine for the Ontario population, the proposed study will determine the costs and health benefits associated with each strategy.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
O'Reilly, Ryan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~